Headache in Multiple Sclerosis: A Narrative Review
- PMID: 38674218
- PMCID: PMC11052044
- DOI: 10.3390/medicina60040572
Headache in Multiple Sclerosis: A Narrative Review
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system characterized by autoimmune-mediated damage to oligodendrocytes and subsequent myelin destruction. Clinical implications: Clinically, the disease presents with many symptoms, often evolving over time. The insidious onset of MS often manifests with non-specific symptoms (prodromal phase), which may precede a clinical diagnosis by several years. Among them, headache is a prominent early indicator, affecting a significant number of MS patients (50-60%). Results: Headache manifests as migraine or tension-type headache with a clear female predilection (female-male ratio 2-3:1). Additionally, some disease-modifying therapies in MS can also induce headache. For instance, teriflunomide, interferons, ponesimod, alemtuzumab and cladribine are associated with an increased incidence of headache. Conclusions: The present review analyzed the literature data on the relationship between headache and MS to provide clinicians with valuable insights for optimized patient management and the therapeutic decision-making process.
Keywords: headache; migraine; multiple sclerosis; prodromal syndrome; tension-type headache.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.J Womens Health (Larchmt). 2024 Apr;33(4):480-490. doi: 10.1089/jwh.2023.0037. Epub 2024 Feb 1. J Womens Health (Larchmt). 2024. PMID: 38301149 Clinical Trial.
-
Teriflunomide for multiple sclerosis.Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article. Review.
-
Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report.Medicine (Baltimore). 2021 Dec 23;100(51):e28246. doi: 10.1097/MD.0000000000028246. Medicine (Baltimore). 2021. PMID: 34941096 Free PMC article.
-
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.Eur J Med Chem. 2013 Feb;60:170-86. doi: 10.1016/j.ejmech.2012.10.055. Epub 2012 Nov 23. Eur J Med Chem. 2013. PMID: 23291119 Review.
-
Update on treatment in multiple sclerosis.Presse Med. 2021 Jun;50(2):104068. doi: 10.1016/j.lpm.2021.104068. Epub 2021 May 24. Presse Med. 2021. PMID: 34033862 Review.
References
-
- MS International Federation Map View. 2023. [(accessed on 11 December 2023)]. Available online: https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms.
-
- Marrodan M., Bensi C., Pappolla A., Rojas J., Gaitán M., Ysrraelit M., Negrotto L., Fiol M., Patrucco L., Cristiano E., et al. Disease activity impacts disability progression in primary progressive multiple sclerosis. Mult. Scler. Relat. Disord. 2019;39:101892. doi: 10.1016/j.msard.2019.101892. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical